hero

Compa Community Jobs

Discover open compensation roles across our Compa Index community network
Hero Box Icon

VP and Above

View Roles
Hero Box Icon

Senior and Director roles

View Roles
Hero Box Icon

Entry Level

View Roles
companies
Jobs
Showing 307 companies
Akamai Technologies
Akamai Technologies
2 jobs

At Akamai, we make life better for billions of people, billions of times a day. Every day, billions of people around the world connect with their favorite brands to shop online, play the latest video games, log into mobile banking apps, learn remotely, share videos with friends, and so much more. They may not know it, but Akamai is there, powering and protecting life online. Over 20 years ago, we set out to solve the toughest challenge of the early Internet: the “World Wide Wait.” And we’ve been solving the Internet’s toughest challenges ever since, working toward our vision of a safer and more connected world. With the world’s most distributed compute platform — from cloud to edge — we make it easy for businesses to develop and run applications, while we keep experiences closer to users and threats farther away. That’s why innovative companies worldwide choose Akamai to build, deliver, and secure their digital experiences. Our leading security, compute, and delivery solutions are helping global companies make life better for billions of people, billions of times a day. Devoted, determined problem-solvers who share a passion for technology, we’re always pushing ground-breaking ideas and driving innovation. Want to power and protect life online, by solving the toughest challenges? Be part of an amazing team. Let’s connect: LinkedIn: https://www.linkedin.com/company/akamai-technologies Twitter: https://twitter.com/akamai Blog: https://www.akamai.com/blog

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
1 jobs

To those who say “impossible, impractical, unrealistic,” we say: “Challenge accepted.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious, and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved our first product, Onpattro (patisiran), which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 2,000+ people. We pride ourselves on fostering a fun, inclusive, and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science magazine Top Employer 5 years in a row ('19-'23), a Boston Globe Top Place to Work 9x in a row ('15-'23), and Fast Company's #1 Best Workplace for Innovators ('22). We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America.